Sachetta LLC Invests $34,000 in Novo Nordisk A/S (NYSE:NVO)

Sachetta LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 325 shares of the company’s stock, valued at approximately $34,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CNB Bank purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $26,000. Pacific Center for Financial Services raised its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Valued Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Bell Investment Advisors Inc raised its stake in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. Finally, Tyler Stone Wealth Management raised its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after acquiring an additional 146 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $134.09 on Thursday. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The firm has a market capitalization of $601.73 billion, a PE ratio of 46.24, a PEG ratio of 1.39 and a beta of 0.43. The business’s 50 day moving average is $128.11 and its 200-day moving average is $116.07. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.